Eyenovia gets FDA approval for Mydcombi ophthalmic spray for mydriasis
Mydcombi is a drug-device combination product that uses Eyenovia’s proprietary drug delivery device Optejet
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 May 23
Mydcombi is a drug-device combination product that uses Eyenovia’s proprietary drug delivery device Optejet
09 May 23
Hospitals are places of healing; at least that’s the way most of us view them. But with the…
08 May 23
The prevalence of chronic wounds is on the rise in the developed world. This is due to its…
05 May 23
The late-stage trial compared the investigational ophthalmic solution against carbachol monotherapy topical ophthalmic solution as well as brimonidine…
05 May 23
Due to the high prevalence of diabetes, much of the academic literature on wound care is centred around…
04 May 23
In the late-stage trial, the investigational amyloid plaque targeting therapy significantly decelerated cognitive and functional decline in patients…
04 May 23
Diabetic foot ulcers have the potential to carry a huge cost, both to patients – who can end…
03 May 23
Accurate diagnosis of gastroenteritis is paramount, given that it is highly infectious and poses health risks to the…
02 May 23
Although microbiology laboratories have witnessed a surge in molecular biology techniques over the last few years, bacterial culturing…
01 May 23
Sepsis is a leading cause of death in hospitals, and yet, there’s very little in the way of…